CVI-VZV-001 not checked

Aribio Lab Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Herpes Zoster
Main trialPhase 2
“To evaluate the immunogenicity of the investigational product (IP) in healthy adults aged 50 years or older and to explore differences in immune responses between the experimental and control groups, and to determine the optimal dose of the IP.”In the company’s words, NCT07481604 on ClinicalTrials.gov

Other drugs for Herpes Zoster

All 19 drugs for Herpes Zoster

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting Jan 2027 Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above
Phase 1Completed 21 Jan 2025 Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow CVI-VZV-001

Following is part of Solo: you see every change to CVI-VZV-001 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in